• VIDEO: ‘Excellent data' on investigational microbiome therapy for recurrent C. difficile

    14 days ago - By Healio

    In this video, C. Jonathan D. Foster, DO, FACOI, discusses results from the PRISM3 trial assessing CP101, an investigational microbiome therapeutic, for recurrent Clostridioides difficile infection.
    The randomized, double blind, placebo-controlled PRISM3 trial, which was presented at the ACG Annual Scientific Meeting, showed that CP101 met its primary endpoint of sustained clinical cure, defined as an absence of C. difficile recurrence, at 8 weeks, with no serious treatment-related adverse events.
    Foster, medical director of gastroenterology and advanced endoscopy at Jefferson Health New
    Read more ...